Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

Executive Summary

After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.

Advertisement

Related Content

Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected
Brandicourt Not Ready To Raise Medivation Bid Just Yet
Sanofi Goes Public With Hostile Medivation Bid
BioMarin: Talazoparib Didn't Fit
Clovis ovarian cancer drug rucaparib dubbed 'breakthrough'
New Xtandi data bolster case for pre-chemo use
FDA defies advisers; OK's AZ's ovarian cancer drug Lynparza
FDA expands Xtandi's prostate cancer use

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel